CN111164103A - 检测和治疗对免疫疗法应答的肝细胞癌类别的方法 - Google Patents

检测和治疗对免疫疗法应答的肝细胞癌类别的方法 Download PDF

Info

Publication number
CN111164103A
CN111164103A CN201880052676.1A CN201880052676A CN111164103A CN 111164103 A CN111164103 A CN 111164103A CN 201880052676 A CN201880052676 A CN 201880052676A CN 111164103 A CN111164103 A CN 111164103A
Authority
CN
China
Prior art keywords
genes
gene
immunotherapy
expression profile
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880052676.1A
Other languages
English (en)
Chinese (zh)
Inventor
D·西亚
J·M·略韦特·艾·拜耳
A·比利亚努埃瓦-罗德里格斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of CN111164103A publication Critical patent/CN111164103A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN201880052676.1A 2017-06-14 2018-06-14 检测和治疗对免疫疗法应答的肝细胞癌类别的方法 Pending CN111164103A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762519711P 2017-06-14 2017-06-14
US62/519,711 2017-06-14
US201862629231P 2018-02-12 2018-02-12
US62/629,231 2018-02-12
PCT/US2018/037579 WO2018232142A1 (en) 2017-06-14 2018-06-14 Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy

Publications (1)

Publication Number Publication Date
CN111164103A true CN111164103A (zh) 2020-05-15

Family

ID=64660235

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880052676.1A Pending CN111164103A (zh) 2017-06-14 2018-06-14 检测和治疗对免疫疗法应答的肝细胞癌类别的方法

Country Status (5)

Country Link
US (1) US11473150B2 (enExample)
EP (1) EP3638695A4 (enExample)
JP (1) JP2020523022A (enExample)
CN (1) CN111164103A (enExample)
WO (1) WO2018232142A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112530581A (zh) * 2020-12-03 2021-03-19 安徽医科大学第一附属医院 一种前列腺癌患者的免疫分子分类系统及其应用
CN112735521A (zh) * 2021-01-22 2021-04-30 安徽医科大学第一附属医院 一种指导选择适用于抗pd-1/pd-l1免疫治疗患者的膀胱癌免疫分类系统
CN113380318A (zh) * 2021-06-07 2021-09-10 天津金域医学检验实验室有限公司 人工智能辅助流式细胞术40cd免疫表型检测方法及系统

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220112564A1 (en) * 2019-02-14 2022-04-14 Merck Sharp & Dohme Corp. Gene expression based biomarker of tumor response to pd-1 antagonists
IL291748A (en) * 2019-11-07 2022-06-01 Oncxerna Therapeutics Inc Classification of growth microenvironments
EP3868897A1 (en) * 2020-02-20 2021-08-25 Worldwide Innovative Network Method for improving the treatment with immune checkpoint blockade therapy
CN113215253B (zh) * 2020-06-05 2022-10-25 冠科生物技术(苏州)有限公司 用于评估鼠类肿瘤模型中的免疫反应的方法和组合物
CN117275733A (zh) * 2023-11-17 2023-12-22 中日友好医院(中日友好临床医学研究所) 基于影像组学预测肿瘤免疫状态及治疗反应的方法及装置
WO2025227286A1 (zh) * 2024-04-28 2025-11-06 浙江大学医学院附属邵逸夫医院 一种识别肝细胞肝癌新亚型的基因模型构建方法及应用
CN118098378B (zh) * 2024-04-28 2024-07-19 浙江大学医学院附属邵逸夫医院 一种识别肝细胞肝癌新亚型的基因模型构建方法及应用
CN119530396A (zh) * 2025-01-22 2025-02-28 中国科学院杭州医学研究所 预测肿瘤免疫治疗效果的标志物及系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110124521A1 (en) * 2008-06-11 2011-05-26 The Ohio State University Use of MiR-26 Family as a Predictive Marker for Hepatocellular Carcinoma and Responsiveness to Therapy
US20140017227A1 (en) * 2011-01-14 2014-01-16 Suk Peng Chew Gene signatures for use with hepatocellular carcinoma
US20150297310A1 (en) * 2014-04-17 2015-10-22 Georgia Regents Research Institute, Inc. Methods for selecting a treatment for cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081442B1 (en) 2006-10-10 2016-08-10 TrovaGene, Inc. Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media
WO2009055480A2 (en) 2007-10-22 2009-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tgf-beta gene expression signature in cancer prognosis
US11242564B2 (en) 2012-07-12 2022-02-08 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
WO2016109546A2 (en) * 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110124521A1 (en) * 2008-06-11 2011-05-26 The Ohio State University Use of MiR-26 Family as a Predictive Marker for Hepatocellular Carcinoma and Responsiveness to Therapy
US20140017227A1 (en) * 2011-01-14 2014-01-16 Suk Peng Chew Gene signatures for use with hepatocellular carcinoma
US20150297310A1 (en) * 2014-04-17 2015-10-22 Georgia Regents Research Institute, Inc. Methods for selecting a treatment for cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
曲建慧等: "肝细胞癌免疫治疗的现状与挑战", 《传染病信息》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112530581A (zh) * 2020-12-03 2021-03-19 安徽医科大学第一附属医院 一种前列腺癌患者的免疫分子分类系统及其应用
CN112530581B (zh) * 2020-12-03 2023-11-21 安徽医科大学第一附属医院 一种前列腺癌患者的免疫分子分类系统及其应用
CN112735521A (zh) * 2021-01-22 2021-04-30 安徽医科大学第一附属医院 一种指导选择适用于抗pd-1/pd-l1免疫治疗患者的膀胱癌免疫分类系统
CN112735521B (zh) * 2021-01-22 2023-09-22 安徽医科大学第一附属医院 一种指导选择适用于抗pd-1/pd-l1免疫治疗患者的膀胱癌免疫分类系统
CN113380318A (zh) * 2021-06-07 2021-09-10 天津金域医学检验实验室有限公司 人工智能辅助流式细胞术40cd免疫表型检测方法及系统

Also Published As

Publication number Publication date
EP3638695A4 (en) 2021-06-30
WO2018232142A1 (en) 2018-12-20
US20210277480A1 (en) 2021-09-09
EP3638695A1 (en) 2020-04-22
JP2020523022A (ja) 2020-08-06
US11473150B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
US11473150B2 (en) Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy
JP6067686B2 (ja) 癌の分子的診断検査
CN109777872B (zh) 肺癌中的t细胞亚群及其特征基因
Hu et al. CLEC1B expression and PD-L1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage
US20170073763A1 (en) Methods and Compositions for Assessing Patients with Non-small Cell Lung Cancer
US20170275705A1 (en) Biomarkers useful for determining response to pd-1 blockade therapy
EP1934377B1 (en) Methods for identifying biomarkers useful in diagnosis of biological states
JP2015536667A (ja) 癌のための分子診断検査
CN113694193A (zh) 检查点阻断和微卫星不稳定性
Davar et al. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
US20110071032A1 (en) Novel tumor marker determination
WO2014022826A2 (en) Biomarker associated with risk of melanoma reoccurrence
Saleh et al. Differential gene expression of tumor-infiltrating CD8+ T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis
Mitra et al. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma
CN109081866B (zh) 癌症中的t细胞亚群及其特征基因
KR20210052709A (ko) 폐암 환자의 면역치료 반응성 예측용 cxcl13 마커 및 이의 용도
WO2015120069A1 (en) Methods and kits for the diagnosis and treatment of pancreatic cancer
CN115232877A (zh) 食管鳞癌的分子分型诊断标记及应用
CN114720687A (zh) Sfrp4作为胃癌预后标志物的应用
Zhao et al. Glucoside xylosyltransferase 2 as a diagnostic and prognostic marker in gastric cancer via comprehensive analysis
Blanco-Heredia et al. Converging and evolving immuno-genomic routes toward immune escape in breast cancer
JP2024526977A (ja) 免疫療法後の治療反応のためのバイオマーカー
US20110183859A1 (en) Inflammatory genes and microrna-21 as biomarkers for colon cancer prognosis
WO2014086765A2 (en) Organized immune response in cancer
US20200263254A1 (en) Method for determining the response of a malignant disease to an immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031046

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200515